Welcome to Gu Mi’s Website
Thank you for visiting! This website serves as a repository of my research works. My published papers and the accompanying software can be downloaded here. Some ongoing works may also be available after a public presentation.
Peer-Reviewed Publications
- Mi, G. (2017). Enhancement of the Adaptive Signature Design for Learning and Confirming in a Single Pivotal Trial. Pharmaceutical Statistics.
- Mi, G., & Di, Y. (2015). The Level of Residual Dispersion Variation and the Power of Differential Expression Tests for RNA-Seq Data. PLOS ONE, 10(4), e0120117.
- Mi, G., Di, Y., & Schafer, D. W. (2015). Goodness-of-fit tests and model diagnostics for negative binomial regression of RNA sequencing data. PLOS ONE, 10(3), e0119254.
- Mi, G., Di, Y., Emerson, S., Cumbie, J. S., & Chang, J. H. (2012). Length bias correction in gene ontology enrichment analysis using logistic regression. PLOS ONE, 7(10), e46128.
- Di, Y., Mi, G., Sun, L., Dong, R., Zhu, H., & Peng, L. (2011, November). Power of association tests in the presence of multiple causal variants. In BMC proceedings (Vol. 5, No. 9, p. 1). BioMed Central.
Conference Presentations
Statistical Conferences
- Mi G. “Enhancement of the Adaptive Signature Design for Learning and Confirming in a Single Pivotal Trial”. Oral Presentation at 2017 ICSA Applied Statistics Symposium.
- Mi G, Nguyen T, and Denne J. “Subgroup Determination by Cross-Validation in STEPP”. Oral Presentation at JSM 2016.
- Mi G. “Cross-Validated STEPP Analysis for Biomarker Subgroup Determination Problems”. Oral Presentation at the 39th Midwest Biopharmaceutical Statistics Workshop (2016).
- Mi G and Di Y. “Power-Robustness Analysis of Statistical Models for RNA-Seq Data”. Oral presentation at 2014 ICSA Joint Applied Statistics Symposium.
- Mi G, Zheng J and Farmen M. “Comparing Methods for Detecting Differential Exon Usage and Splicing from RNA-Seq Data”. Poster presentation at 2013 Summer intern at Eli Lilly & Co. Also presented in 2013 CGRB Fall Conference and Statistics 2013 Oregon.
- Mi G, Di Y, Schafer D and Chang JH. “Goodness-of-Fit Tests and Diagnostics for Negative Binomial Regression of RNA-Seq Data”. Oral presentation at JSM 2013.
- Di Y, Mi G, Emerson S and Schafer D. “Assessing Models of RNA-Sequencing Data”. Poster presentation at JSM 2013.
Medical Conferences
- Arkenau, HT, Bendell, J, Herbst, R, Mi, G, et al. Ramucirumab plus pembrolizumab in previously treated advanced or metastatic biliary tract cancer: A multi-disease phase 1 study. Annals of Oncology. 2017 Jun 1; 28(suppl_3).
- Golan, T, Lin, CC, Fu, S, Wasserstrom, H, Mi, G, et al. A multi-cohort phase 1 study of ramucirumab plus durvalumab: Preliminary safety and clinical activity in patients with locally advanced and unresectable or metastatic gastric or gastroesophageal junction adenocarcinoma. Annals of Oncology. 2017 Jun 1; 28(suppl_3).
- Chau, I, Bendell, JC, Calvo, E, Santana-Davila, R, Arkenau, HT, Mi, G, et al. Ramucirumab (R) plus pembrolizumab (P) in treatment naive and previously treated advanced gastric or gastroesophageal junction (G/GEJ) adenocarcinoma: A multi-disease phase I study. Journal of Clinical Oncology 35, no. 15_suppl (May 2017) 4046-4046.
- Herbst, RS, Martin-Liberal, J, Calvo, E, Isambert, N, Bendell, J, Cassier, P, Jin, J, Mi, G, et al. Previously treated advanced NSCLC cohort from a multi-disease phase 1 study of ramucirumab (R) plus pembrolizumab (P): Efficacy and safety data. Annals of Oncology. 2017 Apr 1;28(suppl_2).
- Genova, C, Varella-Garcia, M, Rivard, C, Socinski, M, Hozak, R, Mi, G, et al. “EGFR FISH as Potential Predictor of Necitumumab Benefit with Chemotherapy in Squamous NSCLC: Subgroup Analyses from SQUIRE”. Journal of Thoracic Oncology, 12(1), pp.S955-S956 (2017).
- Reck, M, Bang, YJ, Goff, L, Wasserstrom, H, Yang, J, Mi, G and Karasarides, M. “Multizentrische, offene Phase 1 Studie mit Ramucirumab plus Durvalumab bei Patienten mit inoperablem lokal fortgeschrittenen oder metastasierten Adenokarzinom des Magens oder gastrooesophagealen Übergangs (G/GEJ), nichtkleinzelligem Lungenkarzinom (NCSLC) oder hepatozellulärem Karzinom (HCC)”. Pneumologie, 71(S 01), p.P5.
- Chau I, Bendell J, Calvo E, Santana-Davila R, Rodon J, Penel N, Arkenau HT, Yang J, Rege J, Mi G, et al. “Interim safety and clinical activity in patients (pts) with advanced gastric or gastroesophageal junction (G/GEJ) adenocarcinoma from a multicohort phase 1 study of ramucirumab (R) plus pembrolizumab (P)”. Poster at 2017 Gastrointestinal Cancers Symposium (ASCO GI).
- Petrylak DP, Arkenau H, Perez-Gracia JL, Krebs M, Santana-Davila R, Yang J, Rege J, Mi G, et al. “A multicohort phase 1 study of ramucirumab (R) plus pembrolizumab (P): interim safety and clinical activity in patients with urothelial carcinoma”. Abstract at 2017 Genitourinary Cancers Symposium (ASCO GU).
- Lin CC, Golan T, Corral J, Moreno V, Chung HC, Wasserstrom H, Yang J, Mi G, et al. “Phase 1 study of ramucirumab (R) plus durvalumab (D) in patients (pts) with locally advanced and unresectable or metastatic gastrointestinal or thoracic malignancies (NCT02572687); phase 1a results”. Proffered paper session at 2016 ESMO Symposium on Immuno-Oncology.
- Bang YJ, Goff LW, Wasserstrom H, Yang J, Mi G, et al. “An open-label, multicenter, phase 1 study of ramucirumab (R) plus durvalumab (D) in patients (pts) with locally advanced and unresectable or metastatic gastric or gastroesophageal junction (G/GEJ) adenocarcinoma, non-small cell lung cancer (NSCLC), or hepatocellular carcinoma (HCC)”. Trial in Progress at 2016 ESMO Symposium on Immuno-Oncology.
- Herbst R, Martin-Liberal J, Calvo E, Isambert N, Bendell J, Cassier J, Perez-Gracia JL, Yang J, Rege J, Mi G, et al. “Interim safety and clinical activity in patients with advanced NSCLC from a multi-cohort phase 1 study of ramucirumab (R) plus pembrolizumab (P)”. Late-Breaking Poster Session at 2016 ESMO Congress.
- Herbst R, Bendell J, Isambert N, Calvo E, Santana-Davila R, Cassier P, Perez-Gracia JL, Yang J, Rege J, Ferry D, Mi G, and Chau I. “A phase 1 study of ramucirumab (R) plus pembrolizumab (P) in patients (pts) with advanced gastric or gastroesophageal junction (G/GEJ) adenocarcinoma, non-small cell lung cancer (NSCLC), or urothelial carcinoma (UC): Phase 1a results” Postes at 2016 ASCO Annual Meeting.
- Rivard C, Boyle T, Ren Q, Kowalewski A, Hozak R, Mi G, et al. “Mutation Prevalence for Oncogenic Drivers in Lung Adenocarcinoma”. Mini Oral Presentation at the 16th World Conference on Lung Cancer (2015).
- Hirsch F, Boyle T, Thatcher N, Paz-Ares L, Varella-Garcia M, Kowalewski A, Hozak R, Mi G, et al. “EGFR IHC and FISH Correlative Analyses (SQUIRE Trial): Necitumumab + Gemcitabine-Cisplatin vs Gemcitabine-Cisplatin in 1st-Line Squamous NSCLC”. Oral Presentation at the 16th World Conference on Lung Cancer (2015).
Expert Reviewer
- BMC Bioinformatics
- BMC Genomics
- Contemporary Clinical Trials
- Contemporary Clinical Trials Communications
- Journal of Biopharmaceutical Statistics
- Journal of Statistical Computation and Simulation
- PLOS ONE
- Research and Reports in Biology
- Advances in Obesity, Weight Management & Control